Cognition Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGTX research report →
Companywww.cogrx.com
Cognition Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD).
- CEO
- Lisa Ricciardi
- IPO
- 2021
- Employees
- 25
- HQ
- Purchase, NY, US
Price Chart
Valuation
- Market Cap
- $94.92M
- P/E
- -5.88
- P/S
- 0.00
- P/B
- 3.85
- EV/EBITDA
- -2.73
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -72.68%
- ROIC
- -141.04%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-23,487,000 · 30.86%
- EPS
- $-0.32 · 62.35%
- Op Income
- $-47,799,000
- FCF YoY
- 13.66%
Performance & Tape
- 52W High
- $3.83
- 52W Low
- $0.22
- 50D MA
- $1.09
- 200D MA
- $1.43
- Beta
- 1.81
- Avg Volume
- 1.10M
Get TickerSpark's AI analysis on CGTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Doyle John Brendan | other | 8,567 |
| Apr 16, 26 | Doyle John Brendan | buy | 10,000 |
| Apr 16, 26 | Ricciardi Lisa | buy | 9,175 |
| Apr 16, 26 | Caggiano Anthony | buy | 10,000 |
| Feb 15, 26 | Ricciardi Lisa | other | 5,850 |
| Feb 15, 26 | Doyle John Brendan | other | 1,560 |
| Feb 15, 26 | Caggiano Anthony | other | 4,680 |
| Feb 3, 26 | Ricciardi Lisa | other | 800,000 |
| Feb 3, 26 | Ricciardi Lisa | other | 26,036 |
| Feb 4, 26 | Ricciardi Lisa | other | 51,704 |
Our CGTX Coverage
We haven't published any research on CGTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CGTX Report →